By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Sarajevo TimesSarajevo TimesSarajevo Times
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Search
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Reading: Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines
Share
Font ResizerAa
Sarajevo TimesSarajevo Times
Font ResizerAa
  • HOME
  • POLITICS
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
  • SPORT
  • ARTS
  • W&N
Search
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Follow US
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2012 Sarajevo Times. All rights reserved.
Sarajevo Times > Blog > BUSINESS > Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines
BUSINESS

Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines

Published: April 6, 2020
Share
SHARE

 

On March 30, 2020, Russian pharmaceutical company, Biocad, announced that it and its partner, ICM d.o.o., recently obtained European registration certification in Bosnia and Herzegovina for two cancer treatment biosimilars:  Acellbia (rituximab), a biosimilar of Roche’s MabThera®, and Herticad (trastuzumab), a biosimilar of Roche’s Herceptin®.  According to Biocad, the registration certificate is valid for five years and initial deliveries are slated to start in June 2020.  Biocad further stated that ICM d.o.o. estimates that the market for these drugs in Bosnia and Herzegovina is $12.7 million.  Biocad’s chief executive, Dmitry Morozov, says the partnership next plans to seek registration in Serbia.

Relatedly, last year the Second Circuit denied Biocad’s Sherman Act antitrust claims against defendants Roche and Genentech for alleged anticompetitive conduct in Russia relating to these biosimilars.  The court found that the Foreign Trade Antitrust Improvements Act of 1982 barred any United States claim because the alleged conduct only resulted in foreign injury and shared no nexus with imports into the United States.

According to the latest data by ICM d.o.o., the market capacity of rituximab and trastuzumab in the country is estimated around $12.7 million. The sales of Russian drugs can start already in June, allowing to decrease government costs for anti-cancer treatment. “By analyzing international markets for launching drugs, we see that our products are in demand,” said Dmitry Morozov, CEO of BIOCAD. “Therefore, in parallel, we conduct registration processes in different countries of Europe. For example, after successful registration in Bosnia and Herzegovina, we are planning to gain access to the Serbian market. These are important steps towards one of the key objectives of our company: to make high-quality therapy available around the world”.

 

HR Inzko: Authorities in Bosnia and Herzegovina must protect Journalists
Excellent Results of the BH Companies at the Cologne Furniture Fair
Court of BiH confirmed Indictment for Milojko Kovacevic over Crimes against Humanity
Catholics, Orthodox Christians and Muslims celebrate Christmas together in Retirement Home
Strong Earthquake hits Bosnia and Herzegovina
TAGGED:#BiH#medicine#pharmacy#russianBosnia
Share This Article
Facebook Whatsapp Whatsapp Telegram Threads Bluesky Email Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article What is the Overall Mine suspected Area in Bosnia and Herzegovina?
Next Article It is Time to think about Life after COVID-19 as the Time doesn’t wait for Anyone
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

Stay Connected

10.2KFollowersLike
10.1KFollowersFollow
414FollowersFollow

Latest News

Banja Luka once again facing a Decision on non-working Sundays
November 18, 2026
Why isn’t Fuel in BiH getting cheaper, despite the Drop in Oil Prices on the Global Market?
November 18, 2026
EUFOR Operation Commander Strengthens Institutional Engagement in Sarajevo
November 18, 2026
BiH defeats Romania at Bilino Polje in this Year’s Edition of League of Nations
November 18, 2026
Interview with Bogdan Marojevic: from an unexpected Discovery to Four World Titles and an Olympic Dream
November 17, 2026
“Orka” from Mostar Wins 54 Medals in the State World Cup
November 17, 2026
From Bosnian Kings to Priceless Works of Art: Take a Peek Behind the Walls of One of the Most Famous Monasteries in BiH
November 17, 2026
Armed Forces of BiH Receive a 40-Ton Crane Worth More Than 1.4 Million BAM from the US
November 17, 2026
Average Fuel Prices in FBiH in a slight Decline
November 17, 2026
SIPA Police Officer arrested
November 17, 2026
Sarajevo TimesSarajevo Times
Follow US
© 2012 Sarajevo Times. All Rights Reserved.
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
Go to mobile version
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?